TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 5.5nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataKi: 6.30nMAssay Description:The purpose of CDK2/Cyclin E1 assay is to evaluate the inhibition (% inhibition, Kiapp and Ki values) of small molecule inhibitors by using a fluores...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 55nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 55nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 55nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 55nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 55nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetNeprilysin/Angiotensin-converting enzyme(Homo sapiens (Human))
Theravance Biopharma R&D Ip
US Patent
Theravance Biopharma R&D Ip
US Patent
Affinity DataKi: 55nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataKi: 177nMAssay Description:The purpose of CDK2/Cyclin E1 assay is to evaluate the inhibition (% inhibition, Kiapp and Ki values) of small molecule inhibitors by using a fluores...More data for this Ligand-Target Pair
TargetProgrammed cell death 1 ligand/protein 1(Homo sapiens)
Yancheng Teachers University
Curated by ChEMBL
Yancheng Teachers University
Curated by ChEMBL
Affinity DataKi: >4.00E+5nMAssay Description:Inhibition of biotinylated tagged PD-1 (unknown origin)/His tagged PD-L1 (unknown origin) protein-protein interaction assessed as inhibition constant...More data for this Ligand-Target Pair
TargetProgrammed cell death 1 ligand/protein 1(Homo sapiens)
Yancheng Teachers University
Curated by ChEMBL
Yancheng Teachers University
Curated by ChEMBL
Affinity DataIC50: 0nMAssay Description:Inhibition of His-tagged PD-1/PD-L1 interaction (unknown origin) incubated for 1 to 4 hrs by HTRF binding assayMore data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 0nMAssay Description:The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocysteine plu...More data for this Ligand-Target Pair
TargetProgrammed cell death 1 ligand/protein 1(Homo sapiens)
Yancheng Teachers University
Curated by ChEMBL
Yancheng Teachers University
Curated by ChEMBL
Affinity DataIC50: 0nMAssay Description:Inhibition of recombinant human PD1 (25 to 167 residues)/human PDL1 (19 to 238 residues) interaction after 40 mins by HTRF assayMore data for this Ligand-Target Pair